121 related articles for article (PubMed ID: 3571931)
1. Changes of hepatitis B virus (HBV) markers during prolonged recombinant interferon alpha-2A treatment of chronic HBV infection.
Mora I; Porres JC; Bartolomé J; Quiroga JA; Gutiez J; Hernández Guio C; Bas C; Carreño V
J Hepatol; 1987 Feb; 4(1):29-36. PubMed ID: 3571931
[TBL] [Abstract][Full Text] [Related]
2. Prolonged (6 months) treatment of chronic hepatitis B virus infection with recombinant leukocyte A interferon.
Carreño V; Porres JC; Mora I; Bartolomé J; Bas C; Gutiez J; Cortés J; Hernández Guio C
Liver; 1987 Dec; 7(6):325-32. PubMed ID: 3437794
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B surface antigen/IgM complexes: relation to receptors for polymerized human serum albumin, hepatitis B virus (HBV) DNA polymerase activity and HBV markers.
Mora I; Carreño V; Porres JC; Gutiez J; Guio CH
Acta Virol; 1987 Mar; 31(2):116-25. PubMed ID: 2886020
[TBL] [Abstract][Full Text] [Related]
4. Placebo-controlled trial of recombinant alpha 2-interferon in Chinese HBsAg-carrier children.
Lai CL; Lok AS; Lin HJ; Wu PC; Yeoh EK; Yeung CY
Lancet; 1987 Oct; 2(8564):877-80. PubMed ID: 2889081
[TBL] [Abstract][Full Text] [Related]
5. Changes in anti-idiotype antibodies against anti-HBs during recombinant interferon treatment of chronic hepatitis B.
Ibarra MZ; Porres JC; Bartolome FJ; Escudero M; Quiroga JA; Carreño V
J Interferon Res; 1990 Aug; 10(4):367-73. PubMed ID: 2230344
[TBL] [Abstract][Full Text] [Related]
6. A controlled study of treatment with recombinant interferon alpha in chronic hepatitis B virus infection: induction and maintenance schedules.
Carreño V; Porres JC; Mora I; Gutiez J; Quiroga JA; Ramón y Cajal S; Oliva H; Compernolle C; Bartolomé J
Antiviral Res; 1987 Oct; 8(3):125-37. PubMed ID: 3501274
[TBL] [Abstract][Full Text] [Related]
7. Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease.
Yuan Q; Song LW; Cavallone D; Moriconi F; Cherubini B; Colombatto P; Oliveri F; Coco BA; Ricco G; Bonino F; Shih JW; Xia NS; Brunetto MR
PLoS One; 2015; 10(6):e0130209. PubMed ID: 26115521
[TBL] [Abstract][Full Text] [Related]
8. Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection.
Zignego AL; Fontana R; Puliti S; Barbagli S; Monti M; Careccia G; Giannelli F; Giannini C; Buzzelli G; Brunetto MR; Bonino F; Gentilini P
Arch Virol; 1997; 142(3):535-44. PubMed ID: 9349299
[TBL] [Abstract][Full Text] [Related]
9. Long-term remission of chronic hepatitis B after alpha-interferon therapy.
Korenman J; Baker B; Waggoner J; Everhart JE; Di Bisceglie AM; Hoofnagle JH
Ann Intern Med; 1991 Apr; 114(8):629-34. PubMed ID: 2003708
[TBL] [Abstract][Full Text] [Related]
10. A controlled trial of recombinant interferon-alpha in Caucasian children with chronic hepatitis B.
Ruiz Moreno M; Jimenez J; Porres JC; Bartolomé J; Moreno A; Carreño V
Digestion; 1990; 45(1):26-33. PubMed ID: 2187723
[TBL] [Abstract][Full Text] [Related]
11. Receptors for polymerized human serum albumin and other hepatitis B virus markers during acute hepatitis B--predictive value of the outcome of the disease.
Mora I; Porres JC; Bartolome FJ; Hernandez Guio C; Gutiez J; Carreño V
Hepatogastroenterology; 1986 Dec; 33(6):250-4. PubMed ID: 3026941
[TBL] [Abstract][Full Text] [Related]
12. Use of quantitative assays for hepatitis B e antigen and IgM antibody to hepatitis B core antigen to monitor therapy in chronic hepatitis B.
Hayashi PH; Beames MP; Kuhns MC; Hoofnagle JH; Di Bisceglie AM
Am J Gastroenterol; 1996 Nov; 91(11):2323-8. PubMed ID: 8931411
[TBL] [Abstract][Full Text] [Related]
13. Anti-hepatitis B core immunoglobulin M in the serologic evaluation of hepatitis B virus infection and simultaneous infection with type B, delta agent, and non-A, non-B viruses.
Perrillo RP; Chau KH; Overby LR; Decker RH
Gastroenterology; 1983 Jul; 85(1):163-7. PubMed ID: 6406288
[TBL] [Abstract][Full Text] [Related]
14. Potential infectivity of blood from HBsAg asymptomatic carriers due to the presence of HBV-DNA and comparison with other markers of HBV infection.
Tedeschi MV; Padilla CF; de Camargo IF; Yoshida CF
Rev Inst Med Trop Sao Paulo; 1989; 31(6):377-83. PubMed ID: 2640512
[TBL] [Abstract][Full Text] [Related]
15. What is the role of serology for the study of chronic hepatitis B virus infection in the age of molecular biology?
Galli C; Orlandini E; Penzo L; Badiale R; Caltran G; Valverde S; Gessoni G
J Med Virol; 2008 Jun; 80(6):974-9. PubMed ID: 18428144
[TBL] [Abstract][Full Text] [Related]
16. Immunoglobulin M antibody to hepatitis B core antigen (IgM anti-HBc) as a marker of interferon therapy in patients with persistent hepatitis B virus infection.
Nakajima E; Tsuji T; Kachi K; Kagawa K; Okanoue T; Takino T; Yamada A; Imanishi J
Biken J; 1987 Mar; 30(1):17-23. PubMed ID: 3675547
[TBL] [Abstract][Full Text] [Related]
17. [A controlled study of treatment with recombinant interferon alpha of chronic hepatitis due to the B virus in childhood].
Carreño V; Porres JC; Ruiz-Moreno M; Gutiez J; Bartolomé FJ
Rev Esp Enferm Dig; 1991 Jan; 79(1):24-8. PubMed ID: 2031770
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of inactive and active, low viraemic HBeAg-negative-hepatitis B virus infection: Benign course towards HBsAg clearance.
Oliveri F; Surace L; Cavallone D; Colombatto P; Ricco G; Salvati N; Coco B; Romagnoli V; Gattai R; Salvati A; Moriconi F; Yuan Q; Bonino F; Brunetto MR
Liver Int; 2017 Nov; 37(11):1622-1631. PubMed ID: 28296013
[TBL] [Abstract][Full Text] [Related]
19. Recurrence-free long-term survival after liver transplantation for hepatitis B using interferon-alpha pretransplant and hepatitis B immune globulin posttransplant.
Tchervenkov JI; Tector AJ; Barkun JS; Sherker A; Forbes CD; Elias N; Cantarovich M; Cleland P; Metrakos P; Meakins JL
Ann Surg; 1997 Sep; 226(3):356-65; discussion 365-8. PubMed ID: 9339942
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B virus DNA in hepatitis B surface antigen-positive blood donors: relation to the hepatitis B e system and outcome in recipients.
Krogsgaard K; Wantzin P; Aldershvile J; Kryger P; Andersson P; Nielsen JO
J Infect Dis; 1986 Feb; 153(2):298-303. PubMed ID: 3944482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
